Abstract: An electronic system for a drug delivery device is provided. The electronic system comprises a dose setting and drive mechanism comprising a first member and a second member, wherein in the dose delivery operation and/or in the dose setting operation, the first member moves, e.g. rotates, relative to the second member; an electronic control unit; an electrical use detection unit operatively connected to the electronic control unit, and configured to generate a use signal in response to the relative movement, e.g. a relative rotational movement, between the first member and the second member, preferably during the dose delivery operation. The electronic system is configured such that it is switched from a first state into a second state by the electronic control unit in response to the use signal, wherein the electronic system has an increased electrical power consumption in the second state as compared to the first state.

Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Abstract: The present disclosure relates to a wearable electronic device. The wearable electronic device includes a housing, a processor arranged inside the housing, and at least a first sensor that is connected to the processor and configured to detect at least one of a mechanical vibration or an acoustic noise caused or generated by a click noise generator of a handheld injection device.

Abstract: The present disclosure provides a method for identifying modulators of protein secretion. Also provided are modulators of protein secretion and use thereof.

Abstract: A wearable medical device includes: a spatial sensor configured to determine distance to objects in an environment in front of the spatial sensor; an acoustic signal generator operable to generate an acoustic signal; a processor; and a memory configured to store instructions which, when executed the processor, cause the wearable medical device to: detect, using the spatial sensor, objects in the environment, calculate the distance to objects detected in the environment, and when the distance to an object is less than a predetermined value, control the acoustic signal generator to generate a first alert.

Abstract: The disclosure relates to a cartridge assembly for a drug delivery device, the cartridge assembly comprising a cartridge containing a drug; a cartridge holder, the cartridge holder defining an interior cartridge holding section, where the cartridge is arranged within the cartridge holding section, wherein the cartridge holder comprises a distal region with a needle connector arranged at a distal end of the distal region and a main body region; a fixing feature which is arranged at the distal region; and a region with reduced mechanical stiffness compared to the stiffness of the main body region, the region with reduced mechanical stiffness being integrated into the distal region and arranged between the needle connector and the fixing feature, such that when the cartridge is moved in a proximal direction, an emerging load is transferred from the cartridge to the fixing feature and to the main body region in the proximal direction.

Abstract: The present invention provides compounds for use in the treatment of pulmonary diseases, in particular asthma, wherein said compounds bind the cytokines IL-13 and TSLP. The treatments according to the present invention can lower the level of fractional exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo. The treatments of the present invention can also reduce eosinophil count, increase FEV1 and/or reduce airway inflammation.

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from acute myeloid leukemia (AML). Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVDs binds to T cell receptor ?? (TCR??), at least ISVD binds to CD33, and at least one ISVD binds to CD123. The present technology also provides nucleic acids, vectors and compositions.

Abstract: Disclosed is a modular system for a drug delivery device with electronic, comprising a mechanical module that comprises a distal end and a proximal end, and a mechanism that is configured to set and/or to deliver a dose of the drug out of the distal end (D) of the mechanical module, an electronic module that comprises a detector unit, and an electronic unit that is operatively coupled to the detector unit, wherein the electronic module is removably mechanically coupled or coupleable to the mechanical module in a proximal end region of the mechanical module.

Abstract: The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I as shown below, wherein X1, X2, X3, X4, Y, R1, R2, R3, and R4 are as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.

Abstract: The present disclosure refers to a switch assembly for an electronic system of a drug delivery device. The switch assembly includes a chassis supporting a PCBA including at least a first electrical contact, a second electrical contact, a third electrical contact and a fourth electrical contact and a ring with a ratchet profile. The chassis moves axially relative to the ring from a first axial position to a second axial position during a first switch operation mode. The chassis and the ring are configured such that the ring rotates relative to the chassis during a second switch operation mode. The first electrical contact and the second electrical contact are arranged such that upon axial movement of the chassis towards the ring during the first switch operation mode, an electrical connection between the first electrical contact and the second electrical contact is closed.

Abstract: This disclosure relates to antigenic multimeric respiratory syncytial virus (RSV) G polypeptides for use in eliciting an immune response to RSV.

Abstract: This disclosure relates to features of an injection device arranged to provide a sensory distraction to a user during insertion of a needle into flesh. According to a first aspect, an injector device includes a housing having a proximal end and a distal end, and configured to receive a container of medicament, a needle housing for holding a needle in a position at the distal end of the housing, and a needle sleeve mounted within the housing, wherein the needle sleeve and needle housing are moveable relative to one another by a user action between a first configuration in which the needle sleeve would enclose a needle, and a second configuration in which a needle would extend from the needle sleeve in the distal direction, wherein the needle sleeve comprises a portion configured to vibrate and/or rotate during motion between the first configuration and the second configuration.

Abstract: The present disclosure relates to peptide IL23 receptor antagonists, their pharmaceutical compositions and their medical use, for example in the treatment of inflammatory bowel diseases such as Crohn's disease.

Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

Abstract: The present invention relates to protein molecules comprising at least one protease-cleavable linker. It also relates to protein molecules obtainable by protease-cleavage of such protein molecules and their use in therapy.

Abstract: A medical device and method for determining a basal dose of insulin and a bolus dose of insulin to be administered for glycemic control is provided. The medical device includes an insulin pump, a control interface including a button configured to select one of a plurality of present bolus insulin doses based on input from a user (e.g., a patient), and a controller configured for executing instructions to determine a basal insulin delivery rate based, at least in part, on a total daily basal insulin dose and to determine the plurality of preset bolus insulin doses based, at least in part, on a total daily bolus insulin dose.

Abstract: The present disclosure relates to an electronic label for a drug delivery device configured for administering a medicament to a patient. The electronic label includes a flexible substrate configured for attachment to a body. The electronic label further includes an electronic display located on the flexible substrate, wherein the electronic display is configured to display a first information content of a first information type, a second information content of a second information type, and a third information content of the first or of the second information type. The electronic label includes a processor connected to the electronic display, which is configured to modify or to control a visual appearance of the electronic display by visualizing at least a portion of the first information content and at least a portion of the third information content separately, simultaneously, sequentially or alternately on the electronic display.

Abstract: The present disclosure relates to a compound of formula (I) wherein R1 represents a hydrogen atom, a —(C1-C6)alkyl group optionally substituted; R2 represents a hydrogen atom, a halogen atom, a —(C1-C6)alkyl group, a —(C3-C7)cycloalkyl group or a —(C2-C6)alkenyl group; R3 represents a hydrogen atom, a halogen atom, a —(C1-C6)alkyl group, a —(C3-C7)cycloalkyl group, or a —(C5-C10)heteroaryl group; X represents a sulfur or oxygen atom; and Ra and Rb represent a hydrogen atom or a —(C1-C6)alkyl group. The present disclosure also relates to a process for their preparation, to novel intermediate compounds, a medicament and a pharmaceutical compostions comprising the compounds of formula (I), as well as their therapeutic uses.